FALBERG KATHRYN E
FALBERG KATHRYN E's purchase track record
FALBERG KATHRYN E has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/30/2022 | NUVB | $484K | -3.1% | -15.2% | +2.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
TTD down 77% while market rises; healthcare integration news. The Trade Desk shares have fallen 77% while the broader market has risen, leading to comparisons with other ad-tech stocks like Alphabet and AppLovin. Recent news highlights a healthcare inventory integration with OptimizeRx, which may be relevant to its advertising capabilities. Despite the significant price drop, the stock trades at a trailing P/E of 13.8, well below its 52-week high of $56.39.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Nuvation Bio Named In Penny Stock Watchlists. Nuvation Bio (NUVB) has been included in recent lists of penny stocks to watch for October 2026. The company's shares are currently trading near a key support level of $4.75, which has been tested multiple times. This technical position provides context for its inclusion in these speculative stock lists.
Transaction History
| RCUS | ▲ Buy | Grant | 5,700 | $0 | 6/11/2026 | View on chart |
| TTD | ▼ Sell | Other | 1,226 | $0 | 3/23/2026 | View on chart |
| TTD | ▼ Sell | Other | 212 | $13K | 3/23/2026 | View on chart |
| TTD | ▼ Sell | Other | 296 | $18K | 3/23/2026 | View on chart |
| TTD | ▼ Sell | Other | 212 | $13K | 3/23/2026 | View on chart |
| TTD | ▼ Sell | Open Market | 102,828 | $3.1M | 3/5/2026 | View on chart |
| TTD | ▼ Sell | Open Market | 50,000 | $1.5M | 3/5/2026 | View on chart |
| RCUS | ▲ Buy | Grant | 13,300 | $0 | 6/10/2025 | View on chart |
| TTD | ▲ Buy | Grant | 4,901 | $0 | 5/27/2025 | View on chart |
| TTD | ▲ Buy | Grant | 845 | $50K | 5/27/2025 | View on chart |
| TTD | ▲ Buy | Grant | 1,183 | $70K | 5/27/2025 | View on chart |
| TTD | ▲ Buy | Grant | 845 | $50K | 5/27/2025 | View on chart |
| TTD | ▲ Buy | Grant | 90 | $6K | 4/15/2025 | View on chart |
| TTD | ▼ Sell | Open Market | 150,000 | $14.7M | 8/13/2024 | View on chart |
| RCUS | ▲ Buy | Grant | 8,400 | $0 | 6/6/2024 | View on chart |
| TTD | ▲ Buy | Grant | 573 | $50K | 5/28/2024 | View on chart |
| TTD | ▲ Buy | Grant | 3,155 | $0 | 5/28/2024 | View on chart |
| TTD | ▲ Buy | Grant | 573 | $50K | 5/28/2024 | View on chart |
| TTD | ▼ Sell | Open Market | 102,935 | $8.4M | 3/8/2024 | View on chart |
| TTD | ▼ Sell | Open Market | 95 | $8K | 3/8/2024 | View on chart |
| TTD | ▼ Sell | Other | 103,030 | $186K | 3/8/2024 | View on chart |
| RCUS | ▼ Sell | Gift | 50,504 | $0 | 6/15/2023 | View on chart |
| RCUS | ▲ Buy | Grant | 6,800 | $0 | 6/15/2023 | View on chart |
| TTD | ▲ Buy | Grant | 4,238 | $0 | 5/25/2023 | View on chart |
| TTD | ▲ Buy | Grant | 799 | $50K | 5/25/2023 | View on chart |
| TTD | ▲ Buy | Grant | 799 | $50K | 5/25/2023 | View on chart |
| TTD | ▼ Sell | Other | 21 | $1K | 2/6/2023 | View on chart |
| NUVB | ▲ Buy | Open Market | 43,000 | $84K | 12/5/2022 | View on chart |
| NUVB | ▲ Buy | Open Market | 47,000 | $93K | 12/2/2022 | View on chart |
| NUVB | ▲ Buy | Open Market | 84,959 | $168K | 12/1/2022 | View on chart |
| NUVB | ▲ Buy | Open Market | 75,041 | $139K | 11/30/2022 | View on chart |
| RCUS | ▲ Buy | Grant | 4,100 | $0 | 6/14/2022 | View on chart |
| TTD | ▲ Buy | Grant | 4,178 | $0 | 5/26/2022 | View on chart |
| TTD | ▲ Buy | Grant | 835 | $50K | 5/26/2022 | View on chart |
| TTD | ▲ Buy | Grant | 267 | $16K | 5/26/2022 | View on chart |
| TTD | ▲ Buy | Grant | 83 | $5K | 5/26/2022 | View on chart |
| TTD | ▼ Sell | Open Market | 80,563 | $8.7M | 11/19/2021 | View on chart |
| TTD | ▼ Sell | Open Market | 47,719 | $5.2M | 11/19/2021 | View on chart |
| TTD | ▼ Sell | Open Market | 21,468 | $2.4M | 11/19/2021 | View on chart |
| TTD | ▼ Sell | Open Market | 250 | $28K | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Arcus Biosciences gets JP Morgan coverage, adds grant program
JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.
Arcus Biosciences gets JP Morgan coverage, adds grant program. JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.